EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity

Timpl R, Sasaki T, Kostka G and Chu ML: Fibulins: A versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 4:479–489. 2003. View Article : Google Scholar : PubMed/NCBI

Obaya AJ, Rua S, Moncada-Pazos A and Cal S: The dual role of fibulins in tumorigenesis. Cancer Lett. 325:132–138. 2012. View Article : Google Scholar : PubMed/NCBI

Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, et al: EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 10:1232011. View Article : Google Scholar : PubMed/NCBI

Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, Mora ME, Nuovo GJ, Cole SE and Viapiano MS: Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 72:3873–3885. 2012. View Article : Google Scholar : PubMed/NCBI

Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S and Nakao A: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar

Luo R, Zhang M, Liu L, Lu S, Zhang CZ and Yun J: Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One. 8:e705112013. View Article : Google Scholar : PubMed/NCBI

Attwa MH and El-Etreby SA: Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 7:1632–1651. 2015. View Article : Google Scholar : PubMed/NCBI

Song EL, Hou YP, Yu SP, Chen SG, Huang JT, Luo T, Kong LP, Xu J and Wang HQ: EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol. 121:174–180. 2011. View Article : Google Scholar

Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN, Faktorova D, Jauch KW and Bruns CJ: EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem. 390:1293–1302. 2009. View Article : Google Scholar : PubMed/NCBI

Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM, Tsai HT, Su LJ and Chen CH: Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol. 222:367–379. 2010. View Article : Google Scholar : PubMed/NCBI

Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, Seidler B, Eser S, Messer M, Reichert M, Pagel P, et al: Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget. 4:277–288. 2013.PubMed/NCBI

Wang Z, Cao CJ, Huang LL, Ke ZF, Luo CJ, Lin ZW, Wang F, Zhang YQ and Wang LT: EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-κB signaling pathway. Oncotarget. 6:14191–14208. 2015. View Article : Google Scholar : PubMed/NCBI

Albig AR, Neil JR and Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI

Xu S, Yang Y, Sun YB, Wang HY, Sun CB and Zhang X: Role of fibulin-3 in lung cancer: In vivo and in vitro analyses. Oncol Rep. 31:79–86. 2014.

Yang T, Qiu H, Bao W, Li B, Lu C, Du G, Luo X, Wang L and Wan X: Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma. PLoS One. 8:e674582013. View Article : Google Scholar : PubMed/NCBI